Biomarker-Defined Metastatic Solid Tumors
Too many loved ones live with uncertainty.
Let’s find answers.
Precision medicine is transforming how we treat cancer. We know that a patient’s response to treatment can depend on the genetic makeup of their cancer and are applying a precision medicine approach to develop new treatments for a number of highly prevalent, biomarker-defined metastatic cancers. Our ambition is for patients with cancer to lead longer, better lives.
Let’s go vertical
We are collaborating with BeiGene to take a vertical inhibition approach to the MAPK pathway. A study combining our MEK inhibitor with BeiGene’s RAF dimer inhibitor represents a unique opportunity to treat patients with MAPK-driven cancers, particularly those with RAS mutations, where rational targeted therapies are urgently needed for patients. We believe that through a potent and optimized vertical inhibition combination therapy approach, we may be able to address several biomarker-defined patient subsets within the broader MAPK-mutated solid tumor space.